NL-OMON40424已完成不适用
A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men. - CEP-37248 SAD Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- TEVA Pharma
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy males
- •18 -45 years
- •BMI of 18.0 to 30.0 kg/m2
- •Weight at least 50 kg
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
招募中
不适用
A study to assess the safety, tolerability, and pharmacokinetics of FM101 after single and multiple ascending dose administration to healthy subjects.ASH (non-alcoholic steatohepatitis)NL-OMON27747Future Medicine Ltd.50
进行中（未招募）
1 期
A Randomised, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2693 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participantsnonalcoholic fatty liver diseaseJPRN-jRCT2071210096Hibi Kazushige22
已完成
不适用
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Donepezil with Glycopyrrolate or Trospium in Elderly Volunteers1004225810012272Alzheimer's diseasedementiaNL-OMON45462Axovant Sciences Ltd.75
进行中（未招募）
不适用
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease.EUCTR2007-002070-61-SEMedImmune LLC800
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease.EUCTR2007-002070-61-CZMedImmune, LLC800